Abiomed: Cardiologists Will Respond To Positive Trends In Unfinished Impella Trial
This article was originally published in The Gray Sheet
Executive Summary
Abiomed expects accelerated adoption of its Impella 2.5 circulatory support device based on partial data from a large study evaluating the system in high-risk, non-emergency angioplasty patients, despite having to stop the trial because it was deemed unlikely to meet its endpoint.
You may also be interested in...
FDA Warns Abiomed About Unlawful Promotion Of Impella Cardiac Pump
FDA says Abiomed is promoting its top-selling Impella 2.5 cardiac pump for unapproved uses, and sent a warning letter to the firm June 10.
FDA Warns Abiomed About Unlawful Promotion Of Impella Cardiac Pump
FDA says Abiomed is promoting its top-selling Impella 2.5 cardiac pump for unapproved uses, and sent a warning letter to the firm June 10.
Abiomed Makes Its Case For Impella In High-Risk Angioplasty Cases
Abiomed and its PROTECT II trial principal investigator say they are confident that a partial analysis of the halted study presented April 3 will be enough to get Impella-based circulatory support into cardiology guidelines as a recommended tool for high-risk angioplasties.